公开(公告)号：US12194049B2

公开(公告)日：2025-01-14

申请号：US17436296

申请日：2020-02-20

Applicant: Guangzhou Century Clinical Research Co., Ltd.

Inventor： Tianyu Sun

IPC: A61K31/54 ,  A61K31/43 ,  A61K31/546 ,  A61P31/04

Abstract: The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.

公开(公告)号：US12187752B2

公开(公告)日：2025-01-07

申请号：US18476050

申请日：2023-09-27

Applicant: Venatorx Pharmaceuticals, Inc.

Inventor： Christopher J. Burns ,  Daniel C. Pevear ,  Luigi Xerri ,  Timothy Henkel ,  Daniel McGarry ,  Lawrence Rosen ,  Gerald Brenner ,  Jean-Baptiste Arlin ,  Ana Fernandez Casares

IPC: A61P31/04 ,  A61K9/00 ,  A61K31/546 ,  A61K31/69 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07F5/02

Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.

公开(公告)号：US20240366643A1

公开(公告)日：2024-11-07

申请号：US18662516

申请日：2024-05-13

Applicant: INSMED INCORPORATED

Inventor： Gina EAGLE ,  Renu GUPTA

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：US20240358844A1

公开(公告)日：2024-10-31

申请号：US18733200

申请日：2024-06-04

Applicant: ORPRO THERAPEUTICS, INC.

Inventor： Peter B. HEIFETZ ,  Haim MOSKOWITZ

IPC: A61K47/64 ,  A61K31/337 ,  A61K31/407 ,  A61K31/427 ,  A61K31/431 ,  A61K31/475 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/665 ,  A61K31/675 ,  A61K31/7036 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/07 ,  A61K38/12 ,  A61K38/13 ,  A61K38/14

CPC classification number: A61K47/64 ,  A61K31/337 ,  A61K31/407 ,  A61K31/427 ,  A61K31/431 ,  A61K31/475 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/665 ,  A61K31/675 ,  A61K31/7036 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/07 ,  A61K38/12 ,  A61K38/13 ,  A61K38/14

Abstract: The present invention is related to a drug delivery composition that includes a thioredoxin homologue protein having an N-terminal monocysteinic active site, with the cysteine residue of the active site in a reduced state and an active agent conjugated to the thioredoxin homologue protein and methods of making and using the composition.

公开(公告)号：US20240335453A1

公开(公告)日：2024-10-10

申请号：US18292703

申请日：2022-07-21

Applicant: University of KwaZulu-Natal ,  University of Zululand

Inventor： Thavendran Govender ,  Tricia Naicker ,  Per I Arvidsson ,  Hendrik G Kruger ,  Byron Peters

IPC: A61K31/546 ,  A61K31/407 ,  A61K31/431 ,  A61P31/04

CPC classification number: A61K31/546 ,  A61K31/407 ,  A61K31/431 ,  A61P31/04

Abstract: A metallo-β-lactamase (MBL) inhibitor of general formula (I) C-A-L (I) in which: C is a functionalised aza-cycloalkane zinc chelating moiety, L is a β-lactam moiety which may be functionalised, and A is a C1-C10 linear or cyclic linker, which may be functionalised, is provided.

公开(公告)号：US20240325302A1

公开(公告)日：2024-10-03

申请号：US18659332

申请日：2024-05-09

Applicant: KING FAISAL UNIVERSITY

Inventor： HANY MOHAMED ABD EL-LATEEF AHMED ,  MAI MOSTAFA KHALAF ALI ,  MOHAMED AHMED EL-MOKHTAR ,  MOHAMMED SHERIF SADDIK IBRAHIM ,  AHMED MOHAMMED ABU-DIEF MOHAMMED

IPC: A61K9/06 ,  A61K31/5377 ,  A61K31/546 ,  A61K47/38 ,  A61K47/69 ,  A61P17/02 ,  A61P31/04 ,  B82Y5/00

CPC classification number: A61K9/06 ,  A61K31/5377 ,  A61K31/546 ,  A61K47/38 ,  A61K47/6903 ,  A61P17/02 ,  A61P31/04 ,  B82Y5/00

Abstract: A combination treatment for antibiotic resistant infections is provided. The combination treatment for antibiotic resistant infections includes zinc oxide nanoparticles loaded with linezolid and ceftriaxone. The combination treatment may be formulated for administration by any desired route, including particularly oral administration or topical administration. The combination treatment may be administered to a subject in need thereof to treat a bacterial infection. The bacterial infection may be caused by any bacterium, including an antibiotic resistant bacterium. The combination treatment may be formulated in a gel for topical administration to improve wound healing and to treat a MRSA infection.

公开(公告)号：US20240317809A1

公开(公告)日：2024-09-26

申请号：US18290214

申请日：2022-05-12

Applicant: University of Pittsburgh-Of the Commonwealth System of Higher Education ,  Peptilogics, Inc.

Inventor： Kenneth Urish ,  Jonathan Steckbeck ,  Despina X. Dobbins ,  Nicholas Pachuda ,  David Huang ,  Bradd N. Picone

IPC: C07K14/005 ,  A61K31/546 ,  A61K38/00 ,  A61P31/04

CPC classification number: C07K14/005 ,  A61K31/546 ,  A61P31/04 ,  A61K38/00 ,  C12N2740/16022 ,  C12N2740/16033

Abstract: Provided in this disclosure are formulations and methods including antimicrobial peptides and at least one antibiotic that can treat or prevent microbial films when applied on an object. Also provided in this disclosure are formulations and methods including antimicrobial peptides and at least one antibiotic that can treat or prevent microbial films when administered to a subject. Also provided in this disclosure are formulations and methods including administering antimicrobial peptides and at least one antibiotic that can improve the survivability of subjects with bacterial infections. Also provided in this disclosure are formulations and methods including administering antimicrobial peptides and at least one antibiotic that can improve the survivability of subjects with periprosthetic joint infection.

公开(公告)号：US20240226000A9

公开(公告)日：2024-07-11

申请号：US18351192

申请日：2023-07-12

Applicant: Dyve Biosciences, Inc.

Inventor： Nathan FITZSIMMONS ,  Ryan BEAL ,  Charles A. HARBERT ,  Audrene RICE ,  Brandon SAND ,  Parshva KOTHARY ,  Bruce SAND

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/48 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24

CPC classification number: A61K9/0014 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/4893 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  C12Y304/24069

Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

公开(公告)号：US20240189384A1

公开(公告)日：2024-06-13

申请号：US18587268

申请日：2024-02-26

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Kenneth Urish ,  Jonathan Brendan Mandell

IPC: A61K38/10 ,  A61K31/546 ,  A61K38/17

CPC classification number: A61K38/10 ,  A61K31/546 ,  A61K38/1729

Abstract: A method of treating or preventing a microbial infection in a patient is provided, along with a wound irrigation system and a composition in the form of an irrigation liquid for reducing microbial load or preventing microbial infection in a wound.

公开(公告)号：US20240082370A1

公开(公告)日：2024-03-14

申请号：US18514046

申请日：2023-11-20

Applicant: Theriva Biologics, Inc.

Inventor： Joseph Sliman

IPC: A61K38/50 ,  A61K9/50 ,  A61K31/546 ,  A61K45/06

CPC classification number: A61K38/50 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/546 ,  A61K45/06 ,  C12Y305/02006

Abstract: The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.